Future of coagulation factor replacement therapy

Summary Over a million patients worldwide currently suffer from hemophilia and other congenital clotting factor deficiencies. Patients affected with hemophilia A and B are treated by intravenous replacement therapy of factor VIII and factor IX, respectively. Current hemophilia treatments have favora...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of thrombosis and haemostasis Vol. 11; pp. 84 - 98
Main Authors:	Peyvandi, F., Garagiola, I., Seregni, S.
Format:	Journal Article
Language:	English
Published:	England Elsevier Limited 01-06-2013
Subjects:	Biotechnology Blood Coagulation Factors - therapeutic use Coagulation factor IX factor VIII fusion proteins half‐life Hemophilia Humans Medical research polyethylene glycols recombinant FVIIa factor IX hemophilia fusion proteins recombinant FVIIa polyethylene glycols factor VIII half-life
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!